{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:37:36Z","timestamp":1777581456924,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["101159018"],"award-info":[{"award-number":["101159018"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15381-5","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T05:20:11Z","timestamp":1764220811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapy-induced remodeling of IgG and plasma N-glycans in breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Martina","family":"Mari\u010di\u0107 Vrban","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Radovani Trbojevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Ramljak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Kirac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Ga\u0107e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Milas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordan","family":"Lauc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragan","family":"Primorac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Gudelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"15381_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3322\/caac.21863","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395. https:\/\/doi.org\/10.3322\/caac.21863.","journal-title":"CA Cancer J Clin"},{"key":"15381_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"15381_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 world health organization classification of tumours of the breast. Histopathology. 2020;77:181\u20135. https:\/\/doi.org\/10.1111\/his.14091.","journal-title":"Histopathology"},{"key":"15381_CR4","doi-asserted-by":"publisher","first-page":"100985","DOI":"10.1016\/j.eclinm.2021.100985","volume":"38","author":"SM Lima","year":"2021","unstructured":"Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021;38:100985. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100985.","journal-title":"EClinicalMedicine"},{"key":"15381_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","volume":"362","author":"V Beral","year":"2003","unstructured":"Beral V. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003;362:419\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(03)14065-2.","journal-title":"Lancet"},{"key":"15381_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","volume":"350","author":"Breast cancer and hormone","year":"1997","unstructured":"Breast cancer and hormone. Replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997;350:1047\u201359. https:\/\/doi.org\/10.1016\/S0140-6736(97)08233-0.","journal-title":"Lancet"},{"key":"15381_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1053\/j.semdp.2022.06.015","volume":"39","author":"Y Hou","year":"2022","unstructured":"Hou Y, Peng Y, Li Z. Update on prognostic and predictive biomarkers of breast cancer. Semin Diagn Pathol. 2022;39:322\u201332. https:\/\/doi.org\/10.1053\/j.semdp.2022.06.015.","journal-title":"Semin Diagn Pathol"},{"key":"15381_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66. https:\/\/doi.org\/10.1038\/s41572-019-0111-2.","journal-title":"Nat Rev Dis Primers"},{"key":"15381_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.critrevonc.2014.03.002","volume":"91","author":"R Sabatier","year":"2014","unstructured":"Sabatier R, Gon\u00e7alves A, Bertucci F. Personalized medicine: present and future of breast cancer management. Crit Rev Oncol Hematol. 2014;91:223\u201333. https:\/\/doi.org\/10.1016\/j.critrevonc.2014.03.002.","journal-title":"Crit Rev Oncol Hematol"},{"key":"15381_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9863092","volume":"2018","author":"X Li","year":"2018","unstructured":"Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and prognostic significance of cancer antigen 15\u2009\u2013\u20093 and carcinoembryonic antigen in breast cancer: a meta-analysis including 12,993 patients. Dis Markers. 2018;2018:1\u201315. https:\/\/doi.org\/10.1155\/2018\/9863092.","journal-title":"Dis Markers"},{"key":"15381_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/1010428318776169","volume":"40","author":"MJ Duffy","year":"2018","unstructured":"Duffy MJ, McDermott EW, Crown J. Blood-based biomarkers in breast cancer: from proteins to circulating tumor cells to circulating tumor DNA. Tumor Biol. 2018;40:101042831877616. https:\/\/doi.org\/10.1177\/1010428318776169.","journal-title":"Tumor Biol"},{"key":"15381_CR12","doi-asserted-by":"publisher","first-page":"iv10","DOI":"10.1093\/annonc\/mdp114","volume":"20","author":"V Kataja","year":"2009","unstructured":"Kataja V, Castiglione M. Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:iv10\u20134. https:\/\/doi.org\/10.1093\/annonc\/mdp114.","journal-title":"Ann Oncol"},{"key":"15381_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35:159\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.11.016.","journal-title":"Ann Oncol"},{"key":"15381_CR14","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41581-019-0129-4","volume":"15","author":"C Reily","year":"2019","unstructured":"Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15:346\u201366. https:\/\/doi.org\/10.1038\/s41581-019-0129-4.","journal-title":"Nat Rev Nephrol"},{"key":"15381_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14789450.2019.1645604","volume":"16","author":"DA Scott","year":"2019","unstructured":"Scott DA, Drake RR. Glycosylation and its implications in breast cancer. Expert Rev Proteomics. 2019;16:665\u201380. https:\/\/doi.org\/10.1080\/14789450.2019.1645604.","journal-title":"Expert Rev Proteomics"},{"key":"15381_CR16","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.3390\/biomedicines10123265","volume":"10","author":"L Peric","year":"2022","unstructured":"Peric L, Vukadin S, Petrovic A, Kuna L, Puseljic N, Sikora R, et al. Glycosylation alterations in cancer cells, prognostic value of glycan biomarkers and their potential as novel therapeutic targets in breast cancer. Biomedicines. 2022;10:3265. https:\/\/doi.org\/10.3390\/biomedicines10123265.","journal-title":"Biomedicines"},{"key":"15381_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10719-021-10001-3","volume":"38","author":"GCM Vreeker","year":"2021","unstructured":"Vreeker GCM, Vangangelt KMH, Bladergroen MR, Nicolardi S, Mesker WE, Wuhrer M, et al. Serum N-glycan profiles differ for various breast cancer subtypes. Glycoconj J. 2021;38:387\u201395. https:\/\/doi.org\/10.1007\/s10719-021-10001-3.","journal-title":"Glycoconj J"},{"key":"15381_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41598-023-51021-3","volume":"14","author":"I Benesova","year":"2024","unstructured":"Benesova I, Nenutil R, Urminsky A, Lattova E, Uhrik L, Grell P, et al. N-glycan profiling of tissue samples to aid breast cancer subtyping. Sci Rep. 2024;14:320. https:\/\/doi.org\/10.1038\/s41598-023-51021-3.","journal-title":"Sci Rep"},{"key":"15381_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-020-01126-7","volume":"124","author":"C Dobie","year":"2021","unstructured":"Dobie C, Skropeta D. Insights into the role of sialylation in cancer progression and metastasis. Br J Cancer. 2021;124:76\u201390. https:\/\/doi.org\/10.1038\/s41416-020-01126-7.","journal-title":"Br J Cancer"},{"key":"15381_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12105","author":"R Saldova","year":"2017","unstructured":"Saldova R, Haakensen VD, R\u00f8dland E, Walsh I, St\u00f6ckmann H, Engebraaten O. Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up. Mol Oncol. 2017. https:\/\/doi.org\/10.1002\/1878-0261.12105.","journal-title":"Mol Oncol"},{"key":"15381_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/annonc\/mdq570","volume":"22","author":"R Saldova","year":"2011","unstructured":"Saldova R, Reuben JM, Abd Hamid UM, Rudd PM, Cristofanilli M. Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Ann Oncol. 2011;22:1113\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdq570.","journal-title":"Ann Oncol"},{"key":"15381_CR22","doi-asserted-by":"publisher","unstructured":"De Leoz MLA, Young LJT, An HJ, Kronewitter SR, Kim J, Miyamoto S, et al. High-Mannose glycans are elevated during. Breast Cancer Progression Mol Cell Proteom. 2010. https:\/\/doi.org\/10.1074\/mcp.M110.002717.","DOI":"10.1074\/mcp.M110.002717"},{"key":"15381_CR23","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1021\/pr401092y","volume":"13","author":"R Saldova","year":"2014","unstructured":"Saldova R, Shehni AA, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, et al. Association of N\u2013glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC. J Proteome Res. 2014;13:2314\u201327. https:\/\/doi.org\/10.1021\/pr401092y.","journal-title":"J Proteome Res"},{"key":"15381_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05039-4","volume":"22","author":"L Li","year":"2024","unstructured":"Li L, Xu Y, Lai Z, Li D, Qiang S, Li Z, et al. Development and validation of a model and nomogram for breast cancer diagnosis based on quantitative analysis of serum disease\u2011specific haptoglobin N\u2011glycosylation. J Transl Med. 2024;22:331. https:\/\/doi.org\/10.1186\/s12967-024-05039-4.","journal-title":"J Transl Med"},{"key":"15381_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2015.12.114","author":"N Kawaguchi-Sakita","year":"2015","unstructured":"Kawaguchi-Sakita N, Kaneshiro-Nakagawa K, Kawashima M, Sugimoto M, Tokiwa M, Suzuki E, et al. Serum Immunoglobulin G Fc region N-glycosylation profiling by matrix-assisted laser desorption\/ionization mass spectrometry can distinguish breast cancer patients from cancer-free controls. Biochem Biophys Res Commun. 2015. https:\/\/doi.org\/10.1016\/j.bbrc.2015.12.114.","journal-title":"Biochem Biophys Res Commun"},{"key":"15381_CR26","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s12885-019-5817-8","volume":"19","author":"AG Gebrehiwot","year":"2019","unstructured":"Gebrehiwot AG, Melka DS, Kassaye YM, Gemechu T, Lako W, Hinou H, Nishimura S-I. Exploring serum and Immunoglobulin G N-glycome as diagnsotic biomarkers for early detection of breast cancer in Ethiopian women. BMC Cancer. 2019;19:588. https:\/\/doi.org\/10.1186\/s12885-019-5817-8.","journal-title":"BMC Cancer"},{"key":"15381_CR27","doi-asserted-by":"publisher","unstructured":"Haslund-Gourley BS, Wigdahl B, Comunale MA. IgG N-glycan signatures as potential diagnostic and prognostic biomarkers. Diagnostics 2023;13:1016.\u00a0https:\/\/doi.org\/10.1186\/s12885-019-5817-8.","DOI":"10.1186\/s12885-019-5817-8"},{"key":"15381_CR28","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.4049\/jimmunol.2400447","volume":"213","author":"B Radovani","year":"2024","unstructured":"Radovani B, Nimmerjahn F. IgG glycosylation: biomarker, functional modulator, and structural component. J Immunol. 2024;213:1573\u201384. https:\/\/doi.org\/10.4049\/jimmunol.2400447.","journal-title":"J Immunol"},{"key":"15381_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/antib13010009","volume":"13","author":"B Rap\u010dan","year":"2024","unstructured":"Rap\u010dan B, Fan\u010dovi\u0107 M, Pribi\u0107 T, Kirac I, Ga\u0107e M, Vu\u010dkovi\u0107 F, et al. Anastrozole and tamoxifen impact on IgG glycome composition dynamics in luminal A and luminal B breast cancers. Antibodies. 2024;13:9. https:\/\/doi.org\/10.3390\/antib13010009.","journal-title":"Antibodies"},{"key":"15381_CR30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12014-020-9267-8","volume":"17","author":"R Qin","year":"2020","unstructured":"Qin R, Yang Y, Chen H, Qin W, Han J, Gu Y, Pan Y, Cheng X, Zhao J, Wang X, Ren S, Sun Y, Gu J. Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling. Clin Proteom. 2020;17:4. https:\/\/doi.org\/10.1186\/s12014-020-9267-8.","journal-title":"Clin Proteom"},{"key":"15381_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158473","volume":"23","author":"J \u0160tambuk","year":"2022","unstructured":"\u0160tambuk J, Vu\u010dkovi\u0107 F, Habazin S, Hani\u0107 M, Novokmet M, Nikolaus S, et al. Distinct longitudinal changes in Immunoglobulin G N-glycosylation associate with therapy response in chronic inflammatory diseases. Int J Mol Sci. 2022;23:8473. https:\/\/doi.org\/10.3390\/ijms23158473.","journal-title":"Int J Mol Sci"},{"key":"15381_CR32","doi-asserted-by":"publisher","first-page":"M111010090","DOI":"10.1074\/mcp.M111.010090","volume":"10","author":"M Pu\u010di\u0107","year":"2011","unstructured":"Pu\u010di\u0107 M, Kne\u017eevi\u0107 A, Vidi\u010d J, Adamczyk B, Novokmet M, Pola\u0161ek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteom. 2011;10:M111010090. https:\/\/doi.org\/10.1074\/mcp.M111.010090.","journal-title":"Mol Cell Proteom"},{"key":"15381_CR33","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1182\/blood-2008-03-144600","volume":"112","author":"M Peipp","year":"2008","unstructured":"Peipp M, Van Bueren JJL, Schneider-Merck T, Bleeker WWK, Dechant M, Beyer T, et al. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 2008;112:2390\u20139. https:\/\/doi.org\/10.1182\/blood-2008-03-144600.","journal-title":"Blood"},{"key":"15381_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"TT Junttila","year":"2011","unstructured":"Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128:347\u201356. https:\/\/doi.org\/10.1007\/s10549-010-1090-x.","journal-title":"Breast Cancer Res Treat"},{"key":"15381_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.18632\/oncotarget.6353","volume":"7","author":"M Di Modica","year":"2016","unstructured":"Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, et al. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. Oncotarget. 2016;7:255\u201365. https:\/\/doi.org\/10.18632\/oncotarget.6353.","journal-title":"Oncotarget"},{"key":"15381_CR36","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.18632\/oncotarget.28064","volume":"12","author":"S Chatterjee","year":"2021","unstructured":"Chatterjee S, Ugonotti J, Lee LY, Everest-Dass A, Kawahara R, Thaysen-Andersen M. Trends in oligomannosylation and \u03b11,2-mannosidase expression in human cancers. Oncotarget. 2021;12:2188\u2013205. https:\/\/doi.org\/10.18632\/oncotarget.28064.","journal-title":"Oncotarget"},{"key":"15381_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146945","author":"K \u0160\u010dup\u00e1kov\u00e1","year":"2021","unstructured":"\u0160\u010dup\u00e1kov\u00e1 K, Adelaja OT, Balluff B, Ayyappan V, Tressler CM, Jenkinson NM, et al. Clinical importance of high-mannose, fucosylated, and complex N-glycans in breast cancer metastasis. JCI Insight. 2021. https:\/\/doi.org\/10.1172\/jci.insight.146945.","journal-title":"JCI Insight"},{"key":"15381_CR38","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.4014\/jmb.2006.06007","volume":"30","author":"JW Choi","year":"2020","unstructured":"Choi JW, Jeong K-H, You JW, Lee JW, Moon B-I, Kim HJ, et al. Serum levels and glycosylation changes of Alpha-1-Acid glycoprotein according to severity of breast cancer in Korean women. J Microbiol Biotechnol. 2020;30:1297\u2013304. https:\/\/doi.org\/10.4014\/jmb.2006.06007.","journal-title":"J Microbiol Biotechnol"},{"key":"15381_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158165","volume":"22","author":"A Chantziou","year":"2021","unstructured":"Chantziou A, Theodorakis K, Polioudaki H, de Bree E, Kampa M, Mavroudis D, et al. Glycosylation modulates plasma membrane trafficking of CD24 in breast cancer cells. Int J Mol Sci. 2021;22:8165. https:\/\/doi.org\/10.3390\/ijms22158165.","journal-title":"Int J Mol Sci"},{"key":"15381_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00929","author":"L Cheng","year":"2020","unstructured":"Cheng L, Cao L, Wu Y, Xie W, Li J, Guan F, et al. Bisecting N-acetylglucosamine on EGFR inhibits malignant phenotype of breast cancer via down-regulation of EGFR\/Erk signaling. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.00929.","journal-title":"Front Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15381-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15381-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:46:18Z","timestamp":1767789978000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15381-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15381"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15381-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the University Hospital for Tumors, Sestre milosrdnice Clinical Hospital Center, Zagreb, Croatia. All participants provided written informed consent prior to inclusion in the study. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GL declares that he is the founder and owner of Genos Glycoscience Research Laboratory, which offers commercial services of glycomic analysis and has several patents in this field. IG and BRT are employees of Genos Glycoscience Research Laboratory. The other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}